# A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

> **NCT03565406** · PHASE1 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 11 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Mocetinostat Induction Phase + Ipilimumab + Nivolumab
- **DRUG:** Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab

## Key facts

- **NCT ID:** NCT03565406
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-25
- **Primary completion:** 2020-01-13
- **Final completion:** 2020-01-13
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
- **Last updated:** 2020-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565406, "A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03565406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*